$3.15
-0.08 (-2.48%)
Open$3.20
Previous Close$3.23
Day High$3.21
Day Low$3.15
52W High$5.07
52W Low$1.81
Volume—
Avg Volume36.6K
Market Cap28.96M
P/E Ratio—
EPS$-1.91
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+912.1% upside
Current
$3.15
$3.15
Target
$31.88
$31.88
$19.01
$31.88 avg
$45.37
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 180.2K | 851.5K | 5.21M |
| Net Income | -17,552,420 | -74,655,850 | -195,079 |
| Profit Margin | -9,756.5% | -9,268.7% | -3.8% |
| EBITDA | -19,268,776 | -86,509,155 | -244,954 |
| Free Cash Flow | — | — | -167,798 |
| Rev Growth | -78.8% | -78.8% | -0.3% |
| Debt/Equity | — | — | 1.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |